Introduction
One of the challenges for gene therapy is the development of efficient vectors for gene delivery in selected target tissues. 1 However, the choice of the vector, the protocol of treatment and the outcome of the therapy are determined not only by the nature of the disease and by the target organ but also by the age of the patient. In general, the intervention early in life has several advantages and newborn gene therapy is an important area of research to be developed. Neonatal gene therapy has the potential to treat an otherwise lethal genetic disease shortly after birth and to minimize the rejection of vectors by establishment of tolerance. Furthermore, many hereditary disorders precociously affect specific organs and gene therapy administered shortly after birth will circumvent this problem preventing the damages caused by the onset of the disease. 2 The proliferative/differentiative status of the cell changes dramatically during the progression of the organism from fetus to adult, and the cycling stage of the target cell may condition the choice of the vector, for example, when the transduction efficiency may be influenced by this parameter. 3, 4 The ability of prenatal diagnosis to identify DNA abnormalities makes early intervention preceding the manifestation of the disease a possible task. 5, 6 The importance of genetic treatment for fetuses diagnosed with inherited diseases has been the subject of several reviews. [7] [8] [9] The treatment of newborns requires the development of the strategies to transduce neonatal tissues and the understanding of how the genetic manipulation will affect host development. Most experimental gene therapy work has thus far focused on applications to the adult organism. However, evidence exists that gene therapy can be applied to the newborn. Treatment of newborn mice with an adenovirus 5-derived vector corrected the metabolic abnormalities caused by glycogenosis 1a. 10 The therapeutic effects were transient, but could be prolonged by the combined treatment with adenoviral and adeno-associated vectors. 11 The quest for long-lasting transgene expression led to the evaluation of retroviral vectors in neonatal gene therapy in a canine model of mucopolysaccharidosis VII. 5, 6 It was shown that the treatment of 2-to 3-day-old dogs with a Moloney murine leukemia virus-based vector, expressing the betaglucuronidase, resulted in a stable transduction of the hepatocytes and prevented the clinical manifestations of the lysosomal storage disease.
Lentiviral vectors represent interesting vehicles for gene therapy because they transduce dividing and nondividing cells and integrate into the host cells for long-lasting expression. [12] [13] [14] [15] [16] Lentiviral transduction of nondividing cells may be dependent on cell type, and human immunodeficiency virus (HIV)-1 accessory proteins may be required for stable transfer in quiescent lymphocytes and hepatocytes. 15, 17, 18 However, induction of proliferation reverts the relative inefficiency of lentiviral transduction of quiescent cells. 19, 20 Therefore, it is possible that newborn tissues, which comprise a high frequency of proliferating cells, may manifest a different sensitivity to lentiviral-mediated gene transduction compared to the corresponding adult counterpart. The majority of lentiviral vectors described in the literature are based on HIV-1, but lentiviral vectors based on HIV-2 were recently described and used in gene transfer protocols. 21, 22 HIV-2-based vectors may have certain advantages over HIV-1-derived vectors. The desirable karyophilic nuclear import function of HIV-2 is encoded by the single-function vpx gene. 23 The same function in HIV-1 is encoded by vpr, which also causes undesirable cell cycle arrest. [24] [25] [26] Therefore, HIV-2-based vectors seem a better choice for targeting proliferating newborn tissues. Furthermore, HIV-2 is generally less pathogenic than HIV-1, 27, 28 and it may be safer to handle in the design and production stage and, presumably, also in the clinical practice. 21, 22 There is only limited information on newborn gene therapy using HIV-1-based vectors 5, 6, 29 and none using HIV-2-based vectors.
We evaluated gene transfer in tissues of newborn mice utilizing an HIV-2-based vector expressing the green fluorescent protein (GFP) reporter gene (HIV-2-GFP). We found that very low doses of HIV-2-GFP could infect and be expressed in newborn mice. Under these conditions, the hepatocytes were the predominant cell type positive for GFP. Moreover, we show that the efficiency of transduction is much greater in the newborn than in the adult mouse. We conclude that newborn gene therapy is a valid approach for gene transfer with HIV-2-based vectors.
Results
Initial experiments were performed to determine whether HIV-2-GFP vector transduced the tissues of newborn mice to express GFP. Mice (2 days old) were injected in the temporal vein with increasing doses of HIV-2-GFP in a volume of 10 ml and the expression of GFP mRNA was determined by RT-polymerase chain reaction (PCR) 2 weeks later in the liver, lung, spleen brain, kidney and thymus. Injection of 10 4 TU (5 Â 10 3 TU/g) of HIV-2-GFP in newborn mice resulted in a low expression of GFP mRNA in the liver, whereas injection of 10 5 TU (5 Â 10 4 TU/g) of HIV-2-GFP caused a much stronger expression of HIV-2-GFP mRNA ( Figure  1a ). Spleen was negative for HIV-2-GFP mRNA even with the highest dose of the vector (Figure 1a ). The brain, kidney and thymus were also always negative (data not shown). In two out of six animals injected with 10 5 TU, a faint band was observed in the lung (data not shown). These results show that HIV-2-GFP vector can transduce newborn mice and it is preferentially expressed in the liver under the conditions used. Having shown that HIV2-GFP can transduce the liver of newborn mice, we asked whether adult mice were equally susceptible to infection. Experiments were performed in which adult mice (8 weeks old) were injected with 10 5 TU of HIV-2-GFP and tested for GFP expression. As shown in Figure  1b , no GFP mRNA expression was detected in the liver of adult mice. A measure of 10 5 TU correspond to 5 Â 10 4 TU/g in the newborn and only 5 Â 10 3 TU/g in the adult. Therefore, we adjusted for body weight and injected 5 Â 10 4 TU/g in the adult to achieve comparable situations. However, even the injection of a similar MOI was insufficient to induce the presence of detectable GFP mRNA in the liver of adult mice (Figure 1b) . The signal of b-actin messenger RNA was used as a positive control. The lung, spleen (Figure 1b) brain, kidney and thymus (data not shown) were always negative. Negative results were also obtained when we assessed the GFP expression by direct fluorescence in the liver, lung and spleen sections (data not shown). These results indicated that the HIV2-GFP was rather inefficient in transducing adult mouse tissues under conditions in which newborn mice were successfully infected. This difference could be accounted for by failure of infection or transgene expression in infected adult cells.
To determine the kinetics of expression of the reporter protein, a new group of mice was injected in the temporal vein 48 h after birth with 10 5 TU HIV-2-GFP and killed 1-6 weeks later. Tissues were collected and analyzed for GFP expression by direct fluorescence and/ or RT-PCR. The results of a representative experiment, in which we histologically evaluated the presence of GFPpositive cells in the mouse liver, are shown in Figure 2 . The bright green fluorescence of the GFP-positive cells can be easily distinguished from the darker background fluorescence caused by the fixation in paraformaldehyde (PAF). At 1 week after infection, we observed the presence of a significant number of GFP-positive cells (Figure 2a ) that were either isolated or organized in doublets (Figure 2e ). The number of doublets grew The pattern of HIV-2-GFP expression analyzed by RT-PCR of total RNA extracted from the liver, lung and spleen of the newborn mice 2 and 5 weeks after infection with 10 5 TU of virus is shown in Figure 3 . GFP mRNA was present in the liver 5 weeks after infection and already detectable 2 weeks after infection. In this group of mice, no positivity was detected in the lungs by RT-PCR as well, indicating that lung positivity occurs with quite low efficiency. The results obtained are in agree- Table 1 summarizes the results obtained for GFP expression in newborn and adult mice tissues analyzed by direct fluorescence and/or RT-PCR, and shows that newborn mice were efficiently transduced by HIV-2-GFP vector and that the liver was the primary target tissue.
The fluorescent cells in the liver of newborn mice infected with HIV-2-GFP were quantified in double-blind experiments. The results are shown in Figure 4 . The temporal appearance of fluorescent cells in the liver is depicted in Figure 4a . The total number of GFP-positive cells/liver increased progressively during the first 5 weeks and plateaued thereafter. During this period, the liver cells proliferate, the liver mass grows and the increase in fluorescent cells can be due to proliferation of the infected cells. We also evaluated the percentage of GFP-positive cells at the various times to asses the transduction efficiency of HIV-2-GFP ( Figure 4a ). The results indicate that the percentage of transduced cells in the liver is rather constant and is close to 2% at each time point. The characteristic of the HIV-2-GFP infection is represented by the formation and enlargement of clusters of positive cells. The kinetics of changes in GFP-positive cluster density in the liver sections was measured ( Figure  4b ) and showed a rapid increase during the first 1-2 weeks, followed by a steady-state level at subsequent time points, indicating the clonal expansion of the infected cells. The increase in total positive cells after the first 2 weeks was largely due to the growth of the clusters, as shown in Figure 4c . At 1 week after infection (open bars), every cluster contained a maximum of three to four cells, whereas 6 weeks after infection (hatched bars), only 22% of the clusters had three to four cells and bigger clusters containing up to nine to ten GFP-positive cells were detected. These results are consistent with the conclusion that the majority of the infected liver cells were proliferating in the growing liver.
No mortality of mice was attributable to the HIV-2-GFP treatment, and the histological examination revealed no signs of hepatotoxicity associated with the viral infection (data not shown). The possible liver toxicity of lentiviral vectors was analyzed by determining plasma alanine aminotransferase (ALT) levels, a sensitive marker for hepatocellular injury. No significant changes in plasma ALT concentrations were observed at 1, 3, 6 and 12 days after injection of 10 5 TU HIV-2-GFP in newborn mice ( Figure 5 ), indicating that lentiviral vector transduces livers of newborn mice without inducing any significant liver toxicity.
The pattern of infection of the lentiviral vector was compared with that of an adenoviral vector expressing the GFP gene (Ad-GFP). Mice were injected 48 h after birth in the temporal vein with 10 8 PFU (plaque-forming unit) of Ad-GFP, a dose previously shown to have a therapeutic effect in newborn mice. No expression of Ad-GFP was detected in the bone marrow, lung, spleen, brain, thymus and kidney (data not shown). These results show that transduction of liver of newborn mice by the adenovirus was limited in magnitude and duration.
To determine whether lentiviral vector was integrated, a two-step PCR amplification was performed ( Figure 7 ). Newborn mice were injected with HIV-2-GFP and killed 2 (2w) and 5 weeks (5w) later. Liver DNA was extracted and subjected to a first round of PCR using a primer based on the murine B2 family of highly repeated dispersed elements 30 together with a primer derived Figure 3 GFP mRNA expression in newborn mice infected with HIV-2-GFP. Mice (2 days old) were injected in the temporal vein with 10 5 TU of HIV-2-GFP in a volume of 10 ml and killed 2 weeks (2w) or 5 weeks (5w) after treatment. Newborn mice injected with equal volume of PBS and killed 5 weeks after treatment were used as a control. Total RNA was extracted from the liver, spleen, and lung of treated and control mice and analyzed by RT-PCR using GFP specific primers (GFP). RNA quality was verified by performing RT-PCR with primers specific for b-actin. A typical experiment carried out using the organs of a single mouse/treatment is shown. Three mice/time point were analyzed. 
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B Salani et al from lentiviral LTR sequences. As B2 regions are repetitive sequences scattered throughout the mouse genome and vectors randomly integrate at different sites, the first PCR reaction generated products with variable sizes that could not be resolved in discrete bands ( Figure  7a ). Limiting amounts of the amplified products ( Figure  7b ) and nonamplified liver DNA (Figure 7c ) of treated (2w, 5w) or untreated (CTRÀ) mice were then used as templates for a second PCR using nested primers derived from lentiviral LTR sequences. As a positive control (CTR+), we used the transfer plasmid DNA amplified with LTR specific primers (Figure 7c ). The expected bands were obtained only from the preamplified products or from the positive control, indicating that HIV-2-GFP genome was embedded in the mouse chromatin. The specificity of B2 sequences for murine DNA was verified performing a nested PCR on genomic DNA of 293T cell line infected with HIV-2-GFP vector using a primer specific for B2 sequences and a primer specific for LTR sequences. As shown in Figure 7d , no amplification was detected (293T-B2), indicating the specificity of the assay used for murine cells with integrated HIV-2. On the other hand, a nested PCR performed on genomic DNA of HIV-2-GFP-infected 293T cell line with a primer specific for Alu repetitive sequences and a primer specific for HIV-2-LTR (293T-Alu) revealed the expected band of 273 bp (Figure 7d ). The cells transduced by HIV-2-GFP vector were classified as hepatocytes on the basis of their morphology and of immunohistochemistry analysis. Liver sections from mice infected 6 weeks earlier with HIV-2-GFP were stained with anti-cytokeratin-18 antibody, a marker for epithelial cells, which stains hepatocytes, and with anti-mouse CD16/CD32 antibody, which stains leukocytes including monocytes and Kuppfer cells (Figure 8 ). HIV-2-GFP-infected fluorescent cells were positive for cytokeratin-18, demonstrating that the majority of the transduced cells were hepatocytes (Figure 8a and b) . The background fluorescence of cytokeratin 18 (CK18)-negative brain cells is shown in Figure 8b1 . Anti-CD16/ CD32 did not stain GFP-positive cells, demonstrating that Kuppfer cells were not infected by the vector (Figure  8c and d) . Liver cells positive for CD16/CD32 were negative for GFP expression (Figure 8d1 ), whereas 65% of murine spleen cells were positive for CD16/CD32, as expected (Figure 8d2 ). We concluded that the vector is preferentially expressed in newborn hepatocytes under the experimental conditions used.
To determine whether adult mice could be infected by HIV-2-GFP under different and more aggressive conditions, we injected 10 5 TU of HIV-2-GFP directly into one lobe of the liver. After 1 week, the injected lobe was excised and the DNA was extracted and tested by PCR for the presence of the vector DNA. We also utilized liver and spleen DNA from newborn (NB) and adult (Adult) mice injected intravenously (i.v.) with 5 Â 10 4 TU/g. As shown in Figure 9a , no positivity was detected by PCR analysis in the spleen of NB and adult mice or in the liver of adult mice injected i.v. with 5 Â 10 4 TU/g. Conversely, PCR analysis shows a specific band of viral DNA in the newborn liver and a faint band in the liver of adult mice injected directly into one lobe (Adult intrahepatically (i.h.)), providing the first indication that adult liver can be infected under these conditions. Amplification of proto-Dbl gene was used as a control of DNA quality.
To increase the sensitivity of detection, the PCR products were Southern blotted and hybridized with a GFP-specific probe. We constructed a calibration curve by amplifying different amounts of genomic DNA derived from the cell line Mirò , which contains two copies of GFP/genome and thus four copies of GFP/cell, and determined that this protocol is about two logs more sensitive than the PCR alone. In fact, while about 4 Â 10
À3
copies of GFP/cell can be clearly detected by PCR, 4 Â 10
À5
copies of GFP/cell can be visualized by subsequent Southern blot (Figure 9b ). The number of copies of GFP vector in liver cells of newborn mice after treatment with 5 Â 10 4 TU/g of HIV-2-GFP vector was quantified by densitometric analysis with a Versa Doc Imaging System. The results indicate that the number of copies of lentivirus/cell was approximately 0.03, which closely correlates with the 2.3% average transduction efficiency observed in 5-week-old animals (Figure 4a ). By Southern blotting of the PCR products, we detected a clear signal in the liver lobe of the adult mouse (Adult i.h.), demonstrating unequivocally the presence of viral DNA, even though the signal was much weaker than that detected in the liver of newborn mice injected with the same relative amount (5 Â 10 4 TU/g) of HIV-2-GFP (Figure 9a, PCR+SOUTHERN) . A faint signal was also detected in the spleen of newborn but not adult mice, demonstrating that this organ is susceptible to HIV-2-GFP infection, although with a very low efficiency. Moreover, Southern blot of PCR products could reveal HIV-2-GFP DNA in the liver of adult mice injected i.v. with 5 Â 10 4 TU/g (Figure 9a ), a condition that does not allow the detection of GFP expression by RT-PCR or direct fluorescence analysis (Figure 1b and Table 1 ). These results provide the first evidence that the HIV-2-GFP viral vector can infect the liver of the adult mouse and that HIV-2-GFP DNA is detectable in the infected liver of the adult mouse but only by Southern blot of PCR detection method. Part of the tissues used for the above experiments was also tested for GFP expression by direct fluorescence (Figure 9 'GFP FLUORESCENCE'). As expected, we observed a significant number of GFPpositive cells in the liver of newborn mice. Furthermore, a small but consistent number of GFP-positive cells ranging from 1 to 3 every five sections was detected in the liver lobe of the adult mouse (Adult i.h.) injected with HIV-2-GFP. No fluorescence was observed in the liver of adult mice injected i.v. with 5 Â 10 4 TU/g or in the spleen of either newborn or adult mice. We conclude that HIV-2-GFP can infect and be expressed in the adult mouse liver, but much less efficiently than in the newborn mouse. Gene therapy may have different constraints, and may require different strategies depending on the age of the recipient because of the variation in proliferative activity and differentiation stage of the tissue. We aimed at defining minimal dose conditions of vector to achieve successful gene transfer in newborn mice because minimal effective dose may reduce some of the potential side effects of viral vectors including toxicity.
We found that inoculation of mice within the first 48 h after birth with 10 5 TU (5 Â 10 4 TU/g) of HIV-2-GFP vector caused preferential transduction of the liver cells of the newborn mouse. This conclusion was based on the detection of the integrated provirus, viral mRNA and GFP-positive cells in the newborn liver, as clearly shown by the presence of fluorescent cells, although utilizing the 5 TU of HIV-2-GFP in a volume of 10 ml and killed 2 (2w) and 5 weeks (5w) later. Mice injected with PBS and killed 5 weeks later were used as negative control (CTRÀ). (a) Liver DNA was amplified with a primer specific for mouse B2 family of highly repeated dispersed elements together with a primer derived from lentiviral LTR sequences. Limited amounts of the amplified products (b) and nonamplified liver DNA (c) were then used as templates for a nested PCR using vector-derived primers amplifying a DNA fragment (LTR) of the indicated size. PCR-positive control was obtained amplifying the Transfer plasmid with the same primers specific for lentiviral LTR sequences (CTR+). Three mice/time point were analyzed and the data shown are representative of the results obtained. (d) 293T genomic DNA was amplified with a primer specific for Alu (293T-Alu) or B2 sequences (293T-B2) together with a primer derived from lentiviral LTR sequences. Limited amounts of the amplified products were then used as template for nested PCR using LTR specific primers.
Newborn gene therapy B Salani et al more sensitive RT-PCR analysis traces of the viral mRNA were detected in the lung of only two out of a total of 21 animals analyzed (Table 1) . The liver is a common target organ of i.v. administered HIV-1-based lentiviral vectors, 15, 20, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] which can also infect the spleen, [32] [33] [34] muscle, 15, 38, 41, 42 nervous system, 12,43-48 and heart. 29, 32, 49, 50 Furthermore, there is evidence that HIV-1-based lentiviruses can transduce kidney 51 and macrophages. [52] [53] [54] [55] While lentiviral vectors pseudotyped with vesicular stomatitis virus G glycoprotein (VSV-G) are not expected to be organ specific, 15, 29, 33 the combination of early intervention and low viral inoculum may be responsible for the selectivity of lentiviral expression in the liver. We calculated that about 2% of the liver cells were transduced by HIV-2-GFP vector between 1 and 6 weeks after infection.
The pattern of HIV-2-GFP expression is characterized by the formation and growth of clusters of positive cells. The frequency of clusters levels off after about 1 week because it is proportional to the number of cells initially infected. Proliferation of infected cells is then responsible for the enlargement of the clusters that can be formed by up to seven to eight cells at 4 weeks of age and for the persistence of a significant number of transduced cells at an older age. Similar clusters of positive cells were described in the liver of newborn dogs transduced with retroviral vectors. 6 These results provide the first evidence that HIV-2-based lentiviral vectors can be utilized successfully for gene therapy in newborn mice.
Older mice were resistant to this treatment because an MOI equivalent to that used in the newborn was insufficient to induce an appreciable number of fluorescent cells in any of the tissues analyzed. A similar conclusion was reached when the GFP mRNA expression was tested by PCR. These results raised the question of the ability of HIV-2-GFP virus to infect liver cells of older animals. We could demonstrate that the vector infects the liver cells of the adult mouse because we could detect viral DNA following injection of HIV-2-GFP directly into one lobe of the liver. Under these conditions, we could also detect fluorescent cells in the injected lobe demonstrating that the virus is not only present but also expressed. I.h. injection results in high MOI in the tissue and the positivity of the liver under such conditions extends to HIV-2, the observations that i.v. injection of high concentrations of HIV-1 can infect the liver of adult mice. 15, 20, 33, 56 However, the infection of the adult liver is quite inefficient as shown by direct comparison of HIV-2-GFP DNA presence in the liver of newborn and adult mice injected i.v. with the same MOI. The vector could be detected in the adult mouse liver only utilizing a very sensitive technique in which PCR amplification is followed by Southern blot (Figure 9 ). While this paper was under review, Park et al 57 reported that HIV-1-based lentiviral vectors transduction efficiency was significantly enhanced in adolescent compared to older mice. Overall, the results of the studies on newborn and adolescent mice support the concept that early gene therapy may be an important strategy for gene transfer with lentiviral vectors. Furthermore, neonatal gene therapy might induce tolerance to subsequent injection of proteins with a low risk for adverse effects, as shown in newborn mice injected with retroviral vectors expressing the canine factor IX. 2 The proliferative activity of newborn liver cells may be an important factor for the elevated transduction efficiency in newborn mice. While lentiviral vectors (HIV-1 and HIV-2) can transduce dividing and nondividing cells, proliferation and/or proliferative stimuli may greatly augment the efficiency of lentiviral infection. 19, 20 Newborn hepatocytes are endowed with proliferative activity, 20 which may be an important factor in high efficiency of hepatocyte transduction in newborn. Proliferative activity may account for the enhanced lentiviral transduction during the progression of the gestational period. [58] [59] [60] [61] [62] [63] [64] We cannot exclude that the route of injection may play a role in the efficiency of infection, although it seems an unlikely possibility. We utilized the Figure 9 Detection of HIV-2-GFP DNA in the tissues of newborn and adult mice. Total cellular DNA was extracted and tested by PCR analysis for the presence of GFP or proto-DBL DNA using specific primers. PCR products were revealed by staining with ethidium bromide (PCR) or by Southern blotting of the PCR products and hybridization with a GFP-specific probe (PCR+SOUTHERN). (a) Newborn (NB) and 8-week-old (Adult) mice were injected with 5 Â 10 4 TU/g of HIV-2-GFP lentiviral vector and killed 5 weeks later. Livers and spleens were collected and used to extract genomic DNA. Mice (8 weeks old ) were injected directly into one lobe of the liver (Adult i.h.) with 10 5 TU of HIV-2-GFP in a volume of 10 ml and killed 1 week later. Liver DNA was extracted and tested for the presence of GFP or proto-DBL DNA. 
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B Salani et al temporal vein, which is accessible and visible during the first 2 days after birth, whereas the tail vein was utilized in older animals. It is also possible that HIV-2 differs from HIV-1 vector in the relative efficiency of gene transfer in the newborn. HIV-2 is genetically different from HIV-1. The fact that the nuclear import function of HIV-2 is encoded by the single function vpr gene may contribute to the high efficiency of transduction, since vpr gene of HIV-1 has both nuclear import and cell cycle arrest activity. Whether the level of transduction achieved here would be therapeutically sufficient will have to be established experimentally for individual pathologies. However, therapeutic responses with very low frequency of transduced cells have been reported. 65 Increasing the doses of lentiviral vector may yield a higher efficiency of transduction and may also be accompanied by toxicity. In the adult mouse, 10 9 TU of HIV-1 lentiviral vectors induced up to 30% transduction of liver cells. 33 Such doses, however, cause toxic reactions, 33 while with lower dose of HIV-2 vector, no toxicity was observed in the newborn mice. Depending on the disease, it may be preferable to transduce a lower number of target cells at an early time point to curb the severity of the onset of the disease or to transduce a larger fraction of cells at a later time point to deal with organ failure.
Materials and methods

Lentiviral vector preparation and titration
Three different plasmids were used to generate the replication-defective HIV-2-GFP:
(a) the Packaging plasmid, pCM-ROD(SD36/EM), 21 derived from the HIV-2 p-ROD(SD36/EM) proviral DNA, where the 5 0 -LTR had been substituted with cytomegalovirus (CMV) promoter and the 3 0 -LTR with a heterologous polyadenylation signal. The latter construct expresses the viral genes gag, pol, tat and rev, but is envelope-minus. It is replication deficient but produces all proteins required for lentiviral vector construction. (b) the Transfer plasmid, pSGT-5(SDM/RRE/CM-GFP), 21 which derives from the proviral clone HIV-2(ST) 21 and contains the 5 0 -and 3 0 -LTRs, the packaging signal, CMV-IE (immediate-early) promoter upstream to the GFP cDNA and a synthetic polylinker with multiple cloning sites located downstream to the inactivated gag gene. This transfer plasmid does not contain the central polypurine tract sequence of HIV. (c) the Env plasmid, pCM-VSV-G, 21 which drives the expression of the envelope of the VSV and is used for pseudotyping the particles generated by the other two constructs.
Human embryonic kidney 293T cells were grown in Dulbecco's modified Eagle's medium (Euroclone, West York, UK) supplemented with 10% heat-inactivated fetal bovine serum (Gibco-BRL, Gaithersburg, MD, USA), glutamine, penicillin and streptomycin (Euroclone, West York, UK), and transfected in T-75 flasks using calcium phosphate protocol (Promega s Mammalian Transfection System Calcium Phosphate). Typically, 2.5 Â 10 6 cells from a subconfluent monolayer culture were transfected with 10 mg each of Packaging, Transfer and Env plasmid DNAs. Cultures were incubated with calcium-DNA aggregates overnight, washed and reincubated with fresh medium. Cells and culture supernatants were harvested 2 days after transfection. Vector was concentrated by pelleting the viral particles of the supernatant by ultracentrifugation at 50 000 g for 1 h using Beckman 70 Ti rotor. The procedure was repeated and the pellet was resuspend 1/200 of the original volume in phosphate-buffered saline (PBS) (pH 7.5). To determine the titer of the vector, 5 Â 10 4 293T cells were seeded in a six-well plate and incubated with serial dilutions of the vector along with 8 mg/ml polybrene for 16-20 h. The cells were washed, detached from the surface and analyzed for GFP expression by flow cytometry 48 h post-transduction. The concentrated lentiviral vector preparations had an infectivity of 5.971.0 Â 10 7 TU/ml.
Adenoviral vector
We used a first-generation adenovirus serotype 5 (Ad-GFP) expressing the GFP gene under the control of a modified CMV-IE promoter/enhancer, especially designed for strong constitutive protein overexpression (Q Á BIO gene-Resnova). Mice were infected with 10 8 PFU corresponding to 10 9 VP (viral particles) of Ad5 CMV-GFP titrated by the optical density method (Q Á BIO geneResnova).
In vivo experiments
B6D2F1 female (8 weeks old) (Charles River-Laboratories), and B6D2F1 newborn mice were used. Animal procedures were approved by our Ethical Committee. Mice (48 h old) were injected into the temporal vein with 10 ml of PBS (pH 7.5) containing 5 Â 10 3 TU/g or 5 Â 10 4 TU/g of HIV-2-GFP vector or 10 8 PFU of Ad-GFP vector.
Mice (8 weeks old) were injected in the tail vein with 100 ml of PBS (pH 7.5) containing 5 Â 10 3 TU/g or 5 Â 10 4 TU/g of HIV-2-GFP vector. One group of 8-weekold mice were anesthetized with xilazine/ketamine (35 mg/kg) and injected directly into one lobe of the liver with 10 ml of PBS (pH 7.5) containing 10 5 TU of HIV-2-GFP vector. Control littermates received equal volume of PBS. Animals were anesthetized with xilazine/ ketamine (35 mg/kg) and perfused intracardially with sterile cold 4% PAF at different times after inoculation. The organs were removed, fixed again in 4% PAF in PBS overnight at 41C and washed several times in PBS. After washing, the tissues were saturated through 5-30% sucrose in PBS for 2-3 days at 41C, embedded in O.C.T. (Tissue-Tek s , Sakura Finetek, EU) compound, frozen and kept at À801C until further processing.
For measurement of plasma ALT activity, new born mice were injected in the temporal vein with 5 Â 10 4 TU/ g of HIV-2-GFP, killed 1, 3, 6 and 12 days later and ALT activity was measured by standard clinical test in plasma samples using a Cobas Integra s 800 Analyzer (Roche).
Analysis of fluorescent tissues
Cryostat sections (20 mm thick) were cut from frozen sample of the liver, spleen, lung, brain, kidney and thymus and kept at À201C until use. Glass slides were mounted with Vectashield-DAPI (4 0 ,6 diamidino-2-phenylindole) mounting medium (Vector Laboratories, Newborn gene therapy B Salani et al Burlingame, CA, USA) and observed with an Olympus BX51 microscope. GFP, R-phycoerythrin (PE) and tetramethyl rhodamine isothiocyanate (TRITC) fluorescent images were captured from the same field at a magnification of Â 100, Â 20 and Â 10 with a digital Olympus camera. For CK18 (Progen Heidelberg, Germany) detection, frozen liver sections were postfixed in acetone/methanol at À201C for 10 min and dried for 1 h. Sections were blocked in 5% normal goat serum, 1% bovine serum albumin (BSA), 0.1% Triton in PBS (PBST) for 1 h at room temperature, washed three times with PBST and incubated with a mouse monoclonal anti-CK18 antibody for 1 h at room temperature. As a control, we used an isotype-matched anti-mouse IgG1 (Pharmingen, San Diego, CA, USA). After washing in PBST, sections were incubated with PE-conjugated goat anti-mouse IgG (Pharmingen, San Diego, CA, USA) for 1 h at room temperature and washed in PBST. Glass slides were mounted with Vectashield-DAPI. For CD16/CD32 (Pharmingen, San Diego, CA, USA) detection, frozen sections were blocked in 5% normal goat serum, 1% BSA in PBS for 1 h at room temperature, washed three times with PBS and incubated with a rat anti-mouse CD16/CD32 monoclonal antibody for 1 h at room temperature. After washing in PBS, sections were incubated with TRITCconjugated goat anti-rat IgG (Pharmingen, San Diego, CA, USA) for 1 h at room temperature. As control, we used an isotype-matched anti-rat IgG2b (Pharmingen, San Diego, CA, USA). After washing in PBS, glass slides were mounted with Vectashield-DAPI and observed with an Olympus BX51 fluorescence microscope at a magnification of Â 40 and Â 100.
To evaluate the percentage of GFP-positive cells transduced by HIV-2-GFP vector three mice/time point were analyzed. In all, 20 randomly collected sections from the livers of newborn mice and five fields/section were analyzed and the percentage of GFP-positive cells was calculated as a function of the total number of cells in the microscopic field visualized with Vectashield-DAPI staining.
The total number of GFP-positive cells in the liver of mice was determined by measuring the weight of the liver and assuming as B10 8 the total number of liver cells in a 6-to 8-week-old mouse. The total number of liver cells/g was calculated and this value was used to determine the total number of GFP-positive cells on the bases of the weight of the liver and the percentage of GFP-positive cells determined at each time point.
PCR and Southern blot
High-molecular-weight DNA, purified from harvested organs of treated and control mice was isolated by lysis with 10 mM Tris (pH 7.5), 100 mM NaCl, 5 mM EDTA, 1% sodium dodecyl sulfate (TNE Buffer), proteinase-K treatment (1 mg/ml) at 571C overnight, phenol/choloroform extraction and ethanol precipitation. Integrated vector DNA in the liver was detected by performing a nested PCR utilizing a B2 primer 33 for ubiquitous repeats found in the mouse genome (B2 family repeats). Extracted genomic DNA (200 ng ) were used as template for the amplification of HIV-2-LTR of the vector genome (B2 sense, 5 0 -GGCTGGTGAGATGGTTCAGT-3 0 and LTR1, 5 0 -CTCCCAGGGCTCAATCTGCCAGC-3 0 ). A nested PCR on 293T cell, infected with HIV-2-GFP viral vector, was performed with a primer specific for Alu sequences. 293T extracted genomic DNA (200 ng) were used as template for the amplification of HIV-2-LTR of the vector genome (Alu, 5 0 -TCCCAGCTACTCGGGAGGCT-3 0 and LTR1, 5 0 -CTCCCAGGGCTCAATCTGCCAGC-3 0 ). The following amplification conditions were used: 10 min at 951C once, 1 min at 941C, 1 min at 571C, 1 min at 721C repeated 35 times followed by an extra 10 min extension at 721C in a total volume of 50 ml. After this amplification, a nested PCR was performed with 1 ml of a 1:4 dilution of the B2 or Alu vector PCR product using two different internal primers (LTR sense and LTR antisense). The primers used, LTR sense (5 0 -TACGAGGCCTTTATTCGA-3 0 ) and LTR antisense (5 0 -GAATACAATGCGAGTAGC-3 0 ), amplify a fragment of 273 bp. The following amplification conditions were used: 10 min at 951C once, 1 min at 941C, 1 min at 551C, 1 min at 721C repeated 35 times followed by an extra 10 min extension at 721C.
For semiquantitative, PCR genomic DNA was extracted from the liver and spleen of newborn and adult mice. Each DNA (1 mg) was amplified with specific primers for proto-DBL gene and GFP cDNA sequences. For detection of HIV-2-GFP vector sequences in the liver of treated newborn mice, extracted genomic DNA was used as template in the PCR to amplify a 150 bp of GFP cDNA (GFP sense, 5 0 -ATCTTCTTCAAGGACGACGG-3 0 and GFP antisense, 5 0 -CTGTTGTAGTTGTACTCCAGC-3 0 ). Amplification conditions were as follows: 951C for 5 min, and 35 cycles of 941C for 1 min, 601C for 1 min and 721C for 1 min, followed by extension at 721C for 7 min. As control, the mouse genomic 300 bp region of the proto-DBL gene 66, 67 was amplified (proto-DBL sense, 5 0 -AAATACCACCCAAGAAGCAGC-3 0 and proto-DBL antisense, 5 0 -ATGACTACCTCCTCCACTTCCT-3 0 ). The following amplification conditions were used: 10 min at 951C once, 1 min at 941C, 1 min at 601C, 1 min at 721C repeated 35 times followed by an extra 10 min extension at 721C.
To increase sensitivity, the PCR amplification products obtained using GFP specific primers were Southern blotted by capillarity transfer to Hybond-N + membranes (Amersham-Pharmacia) and crosslinked by UV radiation. Filters were prehybridized for 4 h at 421C in Hybrisol solution (Oncor, Gaithersburg, MD, USA) and hybridized at 421C overnight with 2 Â 10 6 c.p.m./ml of 32 P ([5 0 -a-32 P]-dCTP, 3000 Ci/mmol; Amersham, Arlington Heights, IL, USA) random-primed-labeled GFP cDNA probe (Life Technologies). Membranes were then washed and autoradiographed using Kodak XAR-5 (Kodak, New York, USA) film. To obtain the standard curve serial dilutions of Mirò cell line, genomic DNA, which contains two integrated copies of GFP cDNA/ genome, 68 were made in murine genomic DNA.
RNA extraction and RT-PCR analysis
For RNA extraction, the liver, spleen and lung were frozen in liquid nitrogen, pulverized and treated with ultra-Pure Trizol s Reagent (Gibco-BRL). For RT-PCR analysis, RNA samples (3 mg) were used to obtain complementary cDNA (RT-for-PCR Kit-Clontech-BDBiosciences). The RT reaction product (2 ml) were subjected to PCR (GFP sense, 5 0 -GAGCTGTTCACC GGGGTGGT-3 0 and GFP antisense, 5 0 -GTACAGCTC GTCCATGCCGA-3 0 ) to generate the 698 bp product corresponding to a region of the GFP cDNA sequence. The RT reaction product (2 ml) were subjected to a control 0 -CCATCTCTTGCTCGAAGT-3 0 ), yielding a 150 bp product. Amplified PCR fragments were separated by electrophoresis on 2% agarose gel and visualized by ethidium bromide staining.
